Q3 Financial Highlights
- Q3 sales grew 10.5% to
$1.72 billion 1, constant currency2 sales grew 11.2% - Q3 TAVR sales grew 8.0% to
$1.24 billion 1, constant currency2 sales grew 8.8% - Q3 TMTT sales grew 44.0% to
$207 million 1,3, constant currency2 sales grew 45.6%3 - Q3 EPS of
$0.53 1; adjusted2 EPS of$0.80 1 which grew 19% versus prior year
2026 Outlook
- Increasing total company sales2 growth guidance to approximately 11.5% from 10% to 11%
- Increasing TAVR sales2 growth guidance to 9.0% to 9.5% from 8% to 9%
- Increasing TMTT sales guidance to
$780 to$790 million from$760 to$780 million - Increasing adjusted EPS guidance to
$2.97 to$3.05 from$2.95 to$3.05 , growing 18% at midpoint versus prior year - 2026 performance and milestone achievements reinforce long-term durable growth
Recent Highlights
- PROGRESS trial marks turning point in the management of moderate AS
- Practice-changing data adding to Edwards’ body of structural heart clinical evidence presented at TCT
- Final TAVR NCD represents important step toward expanding access to timely, high-quality care
U.S . approval of PASCAL Precision for tricuspid repair expands access to differentiated therapyU.S . approval of PASCAL Ace with Capture Clarity simplifies mitral device placement- European approval of SAPIEN M3 RESILIA brings most advanced tissue treatment to patients
U.S . approval of AUTUS addresses lifelong needs of pediatric patients with congenital heart disease
“We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook,” said
Transcatheter Aortic Valve Replacement (TAVR)
In the third quarter, the company reported TAVR sales of
In the
Outside of the
Transcatheter Mitral and Tricuspid Therapies (TMTT)
Third quarter TMTT sales of
The value of the company’s TMTT portfolio is evident as its mitral and tricuspid therapies advance along their adoption curves, allowing physicians to personalize care for each patient’s unique needs.
Adoption of Edwards’ PASCAL system continues to strengthen, supported by the differentiated design and clinical outcomes of the platform and the company’s portfolio approach. During the quarter, the PASCAL ACE with Capture Clarity implant received
The EVOQUE system delivered another strong quarter of growth. As physicians gain experience with the therapy, they are more consistently achieving mild or less residual regurgitation, a result that is increasingly linked to better outcomes for patients. The company also recently received
The company continues to see strong demand for the SAPIEN M3 system for patients who are not suitable for mitral TEER, supported by excellent early clinical outcomes. In addition, Edwards introduced the SAPIEN M3 system with RESILIA tissue in
Surgical
In Surgical, third quarter global sales of
Edwards continues to expand its Surgical portfolio with innovative technologies that address additional unmet patient needs in structural heart surgery. During the quarter, AUTUS became the first
The company is also advancing a measured rollout of ECLIPTIS, its surgical left atrial appendage system in the
TCT 2026 Highlights
At TCT 2026, physicians presented compelling new evidence on the SAPIEN, PASCAL, EVOQUE and SAPIEN M3 systems that deepen the clinical community’s understanding of these therapies and underscore their significant potential to transform care for AS, mitral and tricuspid patients. The breadth and quality of this evidence reflects the strength of Edwards’ innovation strategy and its commitment to setting the benchmark for clinical evidence in structural heart disease.
In TAVR, results from the PROGRESS trial were presented and simultaneously published in
In TMTT, multiple important studies on Edwards’ portfolio of mitral and tricuspid repair and replacement therapies were also shared. The CLASP IITR pivotal trial demonstrated superiority of the PASCAL system plus optimal medical therapy (OMT) compared with OMT alone in patients with severe or greater tricuspid regurgitation. This was driven by significant improvements in health status for those receiving the PASCAL device. In addition, results from 1,100 EVOQUE TTVR patients in the TVT Registry with CMS linkage demonstrated that real-world clinical outcomes of patients with more complex disease replicate those observed in the TRISCEND II clinical trial. Finally, the ENCIRCLE trial studying two-year outcomes of the SAPIEN M3 system, supported transseptal TMVR as a therapeutic option for selected patients with mitral regurgitation.
Additional Financial Results
For the quarter, gross profit margin was 78.5%, or 78.7% adjusted compared to 77.9% in the same period last year. Expected impact from the scaling of newer therapies was more than offset by manufacturing efficiencies and foreign exchange. The company continues to expect adjusted gross profit margin to be at the lower end of its full-year 78% to 79% gross margin guidance, driven by the impacts of currency fluctuations through the company’s hedging program.
Selling, general and administrative expenses in the third quarter were
Operating profit margin in the third quarter was 17.4%, or 30.3% adjusted. Adjusted EPS of
Edwards continues to expect its 2026 effective tax rate, excluding special items, to be at the high end of its previous range of 16% to 19%. This reflects an expectation that side-by-side safe-harbor taxation legislation related to Pillar Two does not come into effect before the end of the year. The company’s tax rate is also impacted by changes to
Cash and cash equivalents were approximately
Edwards has performed share repurchases of approximately
Outlook
As a result of the company’s strong third quarter results, Edwards is increasing its full-year 2026 sales growth rate guidance to approximately 11.5% from 10% to 11% and TAVR product group sales growth guidance to 9% to 9.5% from 8% to 9%. In the fourth quarter and going forward, Edwards assumes that growth will be mainly driven by continued increases in procedure volumes and less by share gains. The underlying market dynamics in TAVR are strong and we saw positive procedure growth trends exiting the quarter. In addition, Edwards is increasing TMTT product group sales guidance to
About
Conference Call and Webcast Information
The company will be hosting a conference call today at
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as “may,” “will,” “should,” “anticipate,” “believe,” “plan,” “project,” “estimate,” “forecast,” “potential,” “predict,” “early clinician feedback,” “expect,” “intend,” “guidance,” “outlook,” “optimistic,” “aspire,” “confident” or other forms of these words or similar expressions and include, but are not limited to, statements made by
Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, and may be outside of the company’s control. The company's forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement, except as required by law. If the company does update or correct one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include: risks related to the failure to successfully innovate and market our products; unsuccessful clinical trials or procedures; manufacturing, logistics or quality issues; competition; dependence on key physicians, research institutions and hospital systems; risks associated with global, economic, political and social conditions; risks related to our international operations; inability to obtain governmental reimbursement or reductions in reimbursement levels; inability to protect our intellectual property; reduced access and demand for our products as a result of, and compliance with, health care legislation and other government regulations; risks related to domestic and foreign income and non-income taxes; use of products in unapproved circumstances and the risk and uncertainties associated with the risks detailed in the company's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended
Edwards,
| ____________________ | |
[1] | Reported sales and diluted EPS are from continuing operations. |
[2] | The company uses the terms “adjusted” and “constant currency” when referring to non-GAAP sales from continuing operations and sales growth information, respectively, which excludes currency exchange rate fluctuations and newly acquired products. Adjusted earnings per share from continuing operations is a non-GAAP item computed on a diluted basis and in this press release also excludes certain litigation (insurance recovery) expenses, net, amortization of intangible assets, restructuring expenses, acquisition contract termination costs, impairment of intangible and long-lived assets, unrealized gain on marketable securities, gain on remeasurement of previously held interest upon business combinations, fair value adjustments to contingent consideration liabilities, separation costs, loss on impairment, and impact of tax law change on R&D credit. See “Non-GAAP Financial Information” and reconciliation tables below. |
[3] | Represents “adjusted” revenues excluding |
Unaudited Consolidated Statements of Operations (in millions, except per share data) | |||||||||||||||
| Three Months Ended |
| Nine Months Ended | ||||||||||||
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
Net sales | $ | 1,715.5 |
|
| $ | 1,553.1 |
|
| $ | 5,105.1 |
|
| $ | 4,498.0 |
|
Cost of sales |
| 369.2 |
|
|
| 345.2 |
|
|
| 1,124.2 |
|
|
| 991.2 |
|
Gross profit |
| 1,346.3 |
|
|
| 1,207.9 |
|
|
| 3,980.9 |
|
|
| 3,506.8 |
|
Selling, general, and administrative expenses |
| 560.9 |
|
|
| 514.6 |
|
|
| 1,644.3 |
|
|
| 1,482.3 |
|
Research and development expenses |
| 281.4 |
|
|
| 280.7 |
|
|
| 823.6 |
|
|
| 811.5 |
|
Certain litigation (insurance recovery) expenses, net |
| (12.7 | ) |
|
| 90.4 |
|
|
| 30.7 |
|
|
| 116.8 |
|
Change in fair value of contingent consideration liabilities |
| — |
|
|
| (12.5 | ) |
|
| — |
|
|
| (12.5 | ) |
Restructuring charges, separation costs, and other |
| 10.7 |
|
|
| 0.1 |
|
|
| 10.7 |
|
|
| 8.5 |
|
Impairment of intangible and long-lived assets |
| 220.2 |
|
|
| 40.0 |
|
|
| 220.2 |
|
|
| 40.0 |
|
Other operating income |
| (13.3 | ) |
|
| (12.5 | ) |
|
| (38.5 | ) |
|
| (52.9 | ) |
Operating income, net |
| 299.1 |
|
|
| 307.1 |
|
|
| 1,289.9 |
|
|
| 1,113.1 |
|
Interest income, net |
| (36.5 | ) |
|
| (38.6 | ) |
|
| (100.0 | ) |
|
| (112.5 | ) |
Loss on impairment |
| — |
|
|
| — |
|
|
| 163.6 |
|
|
| 47.1 |
|
Other non-operating income, net |
| (27.6 | ) |
|
| (2.7 | ) |
|
| (115.7 | ) |
|
| (4.0 | ) |
Income from continuing operations before provision for income taxes |
| 363.2 |
|
|
| 348.4 |
|
|
| 1,342.0 |
|
|
| 1,182.5 |
|
Provision for income taxes |
| 61.8 |
|
|
| 56.1 |
|
|
| 418.5 |
|
|
| 190.7 |
|
Net income from continuing operations |
| 301.4 |
|
|
| 292.3 |
|
|
| 923.5 |
|
|
| 991.8 |
|
Loss from discontinued operations, net of tax |
| — |
|
|
| (2.0 | ) |
|
| — |
|
|
| (13.6 | ) |
Net income |
| 301.4 |
|
|
| 290.3 |
|
|
| 923.5 |
|
|
| 978.2 |
|
Net loss attributable to noncontrolling interest |
| (6.1 | ) |
|
| (0.8 | ) |
|
| (6.6 | ) |
|
| (4.1 | ) |
Net income attributable to | $ | 307.5 |
|
| $ | 291.1 |
|
| $ | 930.1 |
|
| $ | 982.3 |
|
|
|
|
|
|
|
|
| ||||||||
Earnings per share: |
|
|
|
|
|
|
| ||||||||
Basic: |
|
|
|
|
|
|
| ||||||||
Continuing operations | $ | 0.53 |
|
| $ | 0.50 |
|
| $ | 1.61 |
|
| $ | 1.70 |
|
Discontinued operations | $ | — |
|
| $ | — |
|
| $ | — |
|
| $ | (0.02 | ) |
Basic earnings per share | $ | 0.53 |
|
| $ | 0.50 |
|
| $ | 1.61 |
|
| $ | 1.68 |
|
Diluted: |
|
|
|
|
|
|
| ||||||||
Continuing operations | $ | 0.53 |
|
| $ | 0.50 |
|
| $ | 1.61 |
|
| $ | 1.70 |
|
Discontinued operations | $ | — |
|
| $ | — |
|
| $ | — |
|
| $ | (0.03 | ) |
Diluted earnings per share | $ | 0.53 |
|
| $ | 0.50 |
|
| $ | 1.61 |
|
| $ | 1.67 |
|
|
|
|
|
|
|
|
| ||||||||
Weighted-average common shares outstanding: |
|
|
|
|
|
|
| ||||||||
Basic |
| 576.3 |
|
|
| 584.7 |
|
|
| 577.3 |
|
|
| 586.2 |
|
Diluted |
| 577.6 |
|
|
| 585.7 |
|
|
| 578.6 |
|
|
| 587.2 |
|
|
|
|
|
|
|
|
| ||||||||
Operating statistics from continuing operations |
|
|
|
|
|
|
| ||||||||
As a percentage of net sales: |
|
|
|
|
|
|
| ||||||||
Gross profit |
| 78.5 | % |
|
| 77.8 | % |
|
| 78.0 | % |
|
| 78.0 | % |
Selling, general, and administrative expenses |
| 32.7 | % |
|
| 33.1 | % |
|
| 32.2 | % |
|
| 33.0 | % |
Research and development expenses |
| 16.4 | % |
|
| 18.1 | % |
|
| 16.1 | % |
|
| 18.0 | % |
Operating income |
| 17.4 | % |
|
| 19.8 | % |
|
| 25.3 | % |
|
| 24.7 | % |
Income before provision for income taxes |
| 21.2 | % |
|
| 22.4 | % |
|
| 26.3 | % |
|
| 26.3 | % |
Net income from continuing operations |
| 17.6 | % |
|
| 18.8 | % |
|
| 18.1 | % |
|
| 22.0 | % |
|
|
|
|
|
|
|
| ||||||||
Effective tax rate |
| 17.0 | % |
|
| 16.1 | % |
|
| 31.2 | % |
|
| 16.1 | % |
| ____________________ | |||||||||||||||
Note: Numbers may not calculate due to rounding. | |||||||||||||||
Non-GAAP Financial Information
To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles (“GAAP”), the company uses non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the
Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results, and evaluating current performance. These non-GAAP financial measures are used in addition to, and in conjunction with, results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations by investors that, when viewed with its GAAP results, provide a more complete understanding of factors and trends affecting the Company's business and facilitate comparability to historical periods.
Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. A reconciliation of non-GAAP historical financial measures to the most comparable GAAP measure is provided in the tables below.
Fluctuations in currency exchange rates impact the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of currency exchange rate fluctuations from its sales growth provides investors a more useful comparison to historical financial results. The impact of the fluctuations has been detailed in the “Reconciliation of Sales by
Guidance for sales and sales growth rates is provided on a “constant currency basis,” and projections for diluted earnings per share, net income and growth, gross profit margin, and taxes are also provided on a non-GAAP basis, as adjusted, for the items identified above due to the inherent difficulty in forecasting such items without unreasonable efforts. The Company is not able to provide a reconciliation of the non-GAAP guidance to comparable GAAP measures due to the unknown effect, timing, and potential significance of special charges or gains, and management's inability to forecast charges associated with future transactions and initiatives.
The items described below are adjustments to the GAAP financial results in the reconciliations that follow:
Certain Litigation (Insurance Recovery) Expenses, net - The Company incurred certain litigation expense of
Amortization of Intangible Assets - The Company recorded amortization expense related to developed technology and patents in the amount of
Restructuring Expenses - The Company recorded a
Acquisition Contract Termination Costs - The Company recorded expenses of
Separation Costs - The Company recorded expenses of
Impairment of Intangible and Long-Lived Assets - The Company recorded a
Unrealized Gain on
Gain on Remeasurement of Previously Held Interest Upon Business Combinations - The Company recorded a
Change in Fair Value of Contingent Consideration Liabilities - The Company recorded a gain of
Loss on Impairment - The Company recorded a loss on impairment of
Impact of Tax Law Change on R&D Credit - The Company recorded a
Provision for Income Taxes - The income tax impacts of the expenses and gains discussed above are based upon the items' forecasted effect upon the Company's full-year effective tax rate. Adjustments to forecasted items unrelated to the expenses and gains above, as well as impacts related to interim reporting, will have an effect on the income tax impact of these items in subsequent periods.
Unaudited Reconciliation of GAAP to Non-GAAP Financial Information (in millions, except per share and percentage data) | ||||||||||||||||||||||||||||
|
| Three Months Ended | ||||||||||||||||||||||||||
|
|
| Gross Profit Margin |
| Operating Income, net |
| Operating Profit Margin |
| Other Non-operating Income |
| Net Income |
| Diluted EPS |
| Effective Tax Rate | |||||||||||||
GAAP - Continuing Operations |
| $ | 1,715.5 |
| 78.5 | % |
| $ | 299.1 |
|
| 17.4 | % |
| $ | 27.6 |
|
| $ | 301.4 |
|
| $ | 0.53 |
|
| 17.0 | % |
Net loss attributable to noncontrolling interests |
|
| — |
| — |
|
|
| — |
|
| — |
|
|
| — |
|
|
| 6.1 |
|
|
| — |
|
| — |
|
Total attributable to |
|
| 1,715.5 |
| 78.5 | % |
|
| 299.1 |
|
| 17.4 | % |
|
| 27.6 |
|
|
| 307.5 |
|
|
| 0.53 |
|
| 17.0 | % |
Non-GAAP adjustments: (A) (B) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
Certain litigation insurance recovery, net |
|
| — |
| — |
|
|
| (12.7 | ) |
| (0.7 | ) |
|
| — |
|
|
| (10.3 | ) |
|
| (0.02 | ) |
| (0.1 | ) |
Amortization of intangible assets |
|
| — |
| 0.2 |
|
|
| 3.2 |
|
| 0.2 |
|
|
| — |
|
|
| 2.3 |
|
|
| — |
|
| 0.1 |
|
Restructuring expenses |
|
| — |
| — |
|
|
| 2.0 |
|
| 0.1 |
|
|
| — |
|
|
| 1.8 |
|
|
| — |
|
| — |
|
Acquisition contract termination costs |
|
| — |
| — |
|
|
| 8.7 |
|
| 0.5 |
|
|
| — |
|
|
| 7.8 |
|
|
| 0.02 |
|
| (0.1 | ) |
Impairment of intangible and long-lived assets |
|
| — |
| — |
|
|
| 220.2 |
|
| 12.8 |
|
|
| — |
|
|
| 185.4 |
|
|
| 0.33 |
|
| (0.3 | ) |
Unrealized gain on marketable securities |
|
| — |
| — |
|
|
| — |
|
| — |
|
|
| (19.1 | ) |
|
| (14.7 | ) |
|
| (0.03 | ) |
| (0.2 | ) |
Prior period ongoing tax impacts |
|
| — |
| — |
|
|
| — |
|
| — |
|
|
| — |
|
|
| (20.4 | ) |
|
| (0.03 | ) |
| 3.4 |
|
Adjusted |
| $ | 1,715.5 |
| 78.7 | % |
| $ | 520.5 |
|
| 30.3 | % |
| $ | 8.5 |
|
| $ | 459.4 |
|
| $ | 0.80 |
|
| 19.8 | % |
|
| Three Months Ended | |||||||||||||||||||||||||
|
|
| Gross Profit Margin |
| Operating Income, net |
| Operating Profit Margin |
| Other Non-operating Income |
| Net Income |
| Diluted EPS |
| Effective Tax Rate | ||||||||||||
GAAP - Continuing Operations |
| $ | 1,553.1 |
| 77.8 | % |
| $ | 307.1 |
|
| 19.8 | % |
| $ | 2.7 |
| $ | 292.3 |
|
| $ | 0.50 |
|
| 16.1 | % |
Net loss attributable to noncontrolling interests |
|
| — |
| — |
|
|
| — |
|
| — |
|
|
| — |
|
| 0.8 |
|
|
| — |
|
| — |
|
Total attributable to |
|
| 1,553.1 |
| 77.8 | % |
|
| 307.1 |
|
| 19.8 | % |
|
| 2.7 |
|
| 293.1 |
|
|
| 0.50 |
|
| 16.1 | % |
Non-GAAP adjustments: (A) (B) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||
Certain litigation expenses |
|
| — |
| — |
|
|
| 90.4 |
|
| 5.8 |
|
|
| — |
|
| 69.6 |
|
|
| 0.12 |
|
| 1.3 |
|
Amortization of intangible assets |
|
| — |
| 0.1 |
|
|
| 1.7 |
|
| 0.1 |
|
|
| — |
|
| 1.3 |
|
|
| — |
|
| — |
|
Separation costs |
|
| — |
| — |
|
|
| 0.1 |
|
| — |
|
|
| — |
|
| — |
|
|
| — |
|
| — |
|
Impairment of intangible and long-lived assets |
|
| — |
| — |
|
|
| 40.0 |
|
| 2.6 |
|
|
| — |
|
| 38.5 |
|
|
| 0.07 |
|
| (1.1 | ) |
Change in fair value of contingent consideration liabilities |
|
| — |
| — |
|
|
| (12.5 | ) |
| (0.8 | ) |
|
| — |
|
| (12.0 | ) |
|
| (0.02 | ) |
| 0.4 |
|
Prior period ongoing tax impacts |
|
| — |
| — |
|
|
| — |
|
| — |
|
|
| — |
|
| (0.6 | ) |
|
| — |
|
| 0.2 |
|
Adjusted |
| $ | 1,553.1 |
| 77.9 | % |
| $ | 426.8 |
|
| 27.5 | % |
| $ | 2.7 |
| $ | 389.9 |
|
| $ | 0.67 |
|
| 16.9 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
|
| Nine Months Ended | |||||||||||||||||||||||||||||
|
|
| Gross Profit Margin |
| Operating Income |
| Operating Profit Margin |
| Loss on Impairment |
| Other Non-operating Income |
| Net Income |
| Diluted EPS |
| Effective Tax Rate | ||||||||||||||
GAAP - Continuing Operations |
| $ | 5,105.1 |
| 78.0 | % |
| $ | 1,289.9 |
| 25.3 | % |
| $ | 163.6 |
|
| $ | 115.7 |
|
| $ | 923.5 |
|
| $ | 1.61 |
|
| 31.2 | % |
Net loss attributable to noncontrolling interests |
|
| — |
| — |
|
|
| — |
| — |
|
|
| — |
|
|
| — |
|
|
| 6.6 |
|
|
| — |
|
| — |
|
Total attributable to |
|
| 5,105.1 |
| 78.0 | % |
|
| 1,289.9 |
| 25.3 | % |
|
| 163.6 |
|
|
| 115.7 |
|
|
| 930.1 |
|
|
| 1.61 |
|
| 31.2 | % |
Non-GAAP adjustments: (A) (B) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Certain litigation expenses, net |
|
| — |
| — |
|
|
| 30.7 |
| 0.6 |
|
|
| — |
|
|
| — |
|
|
| 22.3 |
|
|
| 0.03 |
|
| (0.1 | ) |
Amortization of intangible assets |
|
| — |
| 0.2 |
|
|
| 9.7 |
| 0.2 |
|
|
| — |
|
|
| — |
|
|
| 7.3 |
|
|
| — |
|
| (0.1 | ) |
Restructuring expenses |
|
| — |
| — |
|
|
| 2.0 |
| — |
|
|
| — |
|
|
| — |
|
|
| 1.8 |
|
|
| — |
|
| — |
|
Acquisition contract termination costs |
|
| — |
| — |
|
|
| 8.7 |
| 0.2 |
|
|
| — |
|
|
| — |
|
|
| 7.8 |
|
|
| 0.02 |
|
| (0.1 | ) |
Impairment of intangible and long-lived assets |
|
| — |
| — |
|
|
| 220.2 |
| 4.3 |
|
|
| — |
|
|
| — |
|
|
| 185.4 |
|
|
| 0.33 |
|
| (1.8 | ) |
Unrealized gain on marketable securities |
|
| — |
| — |
|
|
| — |
| — |
|
|
| — |
|
|
| (19.1 | ) |
|
| (14.7 | ) |
|
| (0.03 | ) |
| 0.1 |
|
Gain on remeasurement of previously held interest upon business combinations |
|
| — |
| — |
|
|
| — |
| — |
|
|
| — |
|
|
| (85.1 | ) |
|
| (77.4 | ) |
|
| (0.13 | ) |
| 1.2 |
|
Loss on impairment |
|
| — |
| — |
|
|
| — |
| — |
|
|
| (163.6 | ) |
|
| — |
|
|
| 125.5 |
|
|
| 0.22 |
|
| (0.7 | ) |
Impact of tax law change on R&D credit |
|
| — |
| — |
|
|
| — |
| — |
|
|
| — |
|
|
| — |
|
|
| 174.4 |
|
|
| 0.30 |
|
| (10.8 | ) |
Adjusted |
| $ | 5,105.1 |
| 78.2 | % |
| $ | 1,561.2 |
| 30.6 | % |
| $ | — |
|
| $ | 11.5 |
|
| $ | 1,362.5 |
|
| $ | 2.35 |
|
| 18.9 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
|
| Nine Months Ended | |||||||||||||||||||||||||||||
|
|
| Gross Profit Margin |
| Operating Income |
| Operating Profit Margin |
| Loss on Impairment |
| Other Non-operating Income |
| Net Income |
| Diluted EPS |
| Effective Tax Rate | ||||||||||||||
GAAP - Continuing Operations |
| $ | 4,498.0 |
| 78.0 | % |
| $ | 1,113.1 |
|
| 24.7 | % |
| $ | 47.1 |
|
| $ | 4.0 |
| $ | 991.8 |
|
| $ | 1.70 |
|
| 16.1 | % |
Net loss attributable to noncontrolling interests |
|
| — |
| — |
|
|
| — |
|
| — |
|
|
| — |
|
|
| — |
|
| 4.1 |
|
|
| — |
|
| — |
|
Total attributable to |
|
| 4,498.0 |
| 78.0 | % |
|
| 1,113.1 |
|
| 24.7 | % |
|
| 47.1 |
|
|
| 4.0 |
|
| 995.9 |
|
|
| 1.70 |
|
| 16.1 | % |
Non-GAAP adjustments: (A) (B) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Certain litigation expenses |
|
| — |
| — |
|
|
| 116.8 |
|
| 2.6 |
|
|
| — |
|
|
| — |
|
| 90.4 |
|
|
| 0.16 |
|
| 0.4 |
|
Amortization of intangible assets |
|
| — |
| 0.1 |
|
|
| 4.9 |
|
| 0.1 |
|
|
| — |
|
|
| — |
|
| 3.9 |
|
|
| — |
|
| — |
|
Separation costs |
|
| — |
| — |
|
|
| 8.5 |
|
| 0.2 |
|
|
| — |
|
|
| — |
|
| 6.6 |
|
|
| 0.01 |
|
| 0.1 |
|
Impairment of intangible and long-lived assets |
|
| — |
| — |
|
|
| 40.0 |
|
| 1.0 |
|
|
| — |
|
|
| — |
|
| 38.5 |
|
|
| 0.07 |
|
| (0.2 | ) |
Change in fair value of contingent consideration liabilities |
|
| — |
| — |
|
|
| (12.5 | ) |
| (0.3 | ) |
|
| — |
|
|
| — |
|
| (12.0 | ) |
|
| (0.02 | ) |
| 0.1 |
|
Loss on impairment |
|
| — |
| — |
|
|
| — |
|
| — |
|
|
| (47.1 | ) |
|
| — |
|
| 37.6 |
|
|
| 0.06 |
|
| 0.1 |
|
Prior period ongoing tax impacts |
|
| — |
| — |
|
|
| — |
|
| — |
|
|
| — |
|
|
| — |
|
| (0.6 | ) |
|
| — |
|
| 0.1 |
|
Adjusted |
| $ | 4,498.0 |
| 78.1 | % |
| $ | 1,270.8 |
|
| 28.3 | % |
| $ | — |
|
| $ | 4.0 |
| $ | 1,160.3 |
|
| $ | 1.98 |
|
| 16.7 | % |
| ____________________ | |
| (A) | See description of non-GAAP adjustments under “Non-GAAP Financial Information.” |
| (B) | The tax effect on non-GAAP adjustments is calculated based upon the impact of the relevant tax jurisdictions’ statutory tax rates on the Company’s estimated annual effective tax rate, or discrete rate in the quarter, as applicable. The impact on the effective tax rate is reflected on each individual non-GAAP adjustment line item. |
RECONCILIATION OF SALES BY PRODUCT GROUP AND REGION | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| 2025 Adjusted |
|
| ||||||||||
Sales by |
| 3Q 2026 |
| 3Q 2025 |
| Change |
| GAAP Growth Rate* |
| FX Impact |
| 3Q 2025 Adjusted Sales |
| Constant Currency Growth Rate * | ||||||||
Transcatheter Aortic Valve Replacement |
| $ | 1,241.6 |
| $ | 1,149.9 |
| $ | 91.7 |
| 8.0 | % |
| $ | (7.9 | ) |
| $ | 1,142.0 |
| 8.8 | % |
Transcatheter Mitral and Tricuspid Therapies (A) |
|
| 209.5 |
|
| 145.2 |
|
| 64.3 |
| 44.3 | % |
|
| (1.5 | ) |
|
| 143.7 |
| 45.9 | % |
Surgical (B) |
|
| 264.4 |
|
| 258.0 |
|
| 6.4 |
| 2.5 | % |
|
| (0.4 | ) |
|
| 257.6 |
| 2.8 | % |
Total |
| $ | 1,715.5 |
| $ | 1,553.1 |
| $ | 162.4 |
| 10.5 | % |
| $ | (9.8 | ) |
| $ | 1,543.3 |
| 11.2 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| 2025 Adjusted |
|
| |||||||||
Sales by |
| YTD 3Q 2026 |
| YTD 3Q 2025 |
| Change |
| GAAP Growth Rate* |
| FX Impact |
| YTD 3Q 2025 Adjusted Sales |
| Constant Currency Growth Rate * | |||||||
Transcatheter Aortic Valve Replacement |
| $ | 3,697.2 |
| $ | 3,327.4 |
| $ | 369.8 |
| 11.1 | % |
| $ | 32.5 |
| $ | 3,359.9 |
| 10.1 | % |
Transcatheter Mitral and Tricuspid Therapies (A) |
|
| 583.2 |
|
| 394.9 |
|
| 188.3 |
| 47.7 | % |
|
| 8.3 |
|
| 403.2 |
| 44.7 | % |
Surgical (B) |
|
| 824.7 |
|
| 775.7 |
|
| 49.0 |
| 6.3 | % |
|
| 13.4 |
|
| 789.1 |
| 4.6 | % |
Total |
| $ | 5,105.1 |
| $ | 4,498.0 |
| $ | 607.1 |
| 13.5 | % |
| $ | 54.2 |
| $ | 4,552.2 |
| 12.2 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
| 2025 Adjusted |
|
| ||||||||||
Sales by Region (QTD) - Continuing Operations |
|
| 3Q 2026 |
|
| 3Q 2025 |
| Change |
| GAAP Growth Rate* |
| FX Impact |
| 3Q 2025 Adjusted Sales |
| Constant Currency Growth Rate * | ||||||
| $ | 1,007.6 |
| $ | 907.5 |
| $ | 100.1 |
| 11.0 | % |
| $ | — |
|
| $ | 907.5 |
| 11.0 | % | |
|
| 414.6 |
|
| 387.9 |
|
| 26.7 |
| 6.9 | % |
|
| (4.3 | ) |
|
| 383.6 |
| 8.2 | % | |
|
| 92.0 |
|
| 90.1 |
|
| 1.9 |
| 2.2 | % |
|
| (8.1 | ) |
|
| 82.0 |
| 12.2 | % | |
Rest of World |
|
| 201.3 |
|
| 167.6 |
|
| 33.7 |
| 20.2 | % |
|
| 2.6 |
|
|
| 170.2 |
| 18.3 | % |
Outside of |
|
| 707.9 |
|
| 645.6 |
|
| 62.3 |
| 9.7 | % |
|
| (9.8 | ) |
|
| 635.8 |
| 11.5 | % |
Total |
| $ | 1,715.5 |
| $ | 1,553.1 |
| $ | 162.4 |
| 10.5 | % |
| $ | (9.8 | ) |
| $ | 1,543.3 |
| 11.2 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
| 2025 Adjusted |
|
| ||||||||||
Sales by Region (YTD) - Continuing Operations |
| YTD 3Q 2026 |
| YTD 3Q 2025 |
| Change |
| GAAP Growth Rate* |
| FX Impact |
| YTD 3Q 2025 Adjusted Sales |
| Constant Currency Growth Rate * | ||||||||
| $ | 2,948.7 |
| $ | 2,636.1 |
| $ | 312.6 |
| 11.9 | % |
| $ | — |
|
| $ | 2,636.1 |
| 11.9 | % | |
|
| 1,296.8 |
|
| 1,107.9 |
|
| 188.9 |
| 17.0 | % |
|
| 54.0 |
|
|
| 1,161.9 |
| 11.6 | % | |
|
| 279.0 |
|
| 267.2 |
|
| 11.8 |
| 4.4 | % |
|
| (16.8 | ) |
|
| 250.4 |
| 11.4 | % | |
Rest of World |
|
| 580.6 |
|
| 486.8 |
|
| 93.8 |
| 19.3 | % |
|
| 17.0 |
|
|
| 503.8 |
| 15.3 | % |
Outside of |
|
| 2,156.4 |
|
| 1,861.9 |
|
| 294.5 |
| 15.8 | % |
|
| 54.2 |
|
|
| 1,916.1 |
| 12.6 | % |
Total |
| $ | 5,105.1 |
| $ | 4,498.0 |
| $ | 607.1 |
| 13.5 | % |
| $ | 54.2 |
|
| $ | 4,552.2 |
| 12.2 | % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
| ____________________ | |
| (A) | Revenues related to Implantable Heart Failure Management of |
| (B) | Revenues related to a transitional service agreement from 2025 sale of our non-product group of |
* | Numbers may not calculate due to rounding. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20261104708591/en/
Media:
Investors:
Source: